Perspective Therapeutics, Inc.
CATX
Positions held
Your positionsCATX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $309.35M | Enterprise value | $76.44M | Trailing P/E | — | Forward P/E | -2.65 |
| PEG | — | Price / book | 0.95 | Beta | 1.85 | Dividend yield | 0.00% |
| Revenue growth | -72.1% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -361.2% |
| Profit margin | 0.0% | ROE | -39.6% | ROA | -22.3% | Debt / equity | 0.01 |
| Current ratio | 6.61 | Free cash flow | -$69.43M | Analyst recommendation | strong_buy | Mean target | $12.29 |
| 52w high | $6.16 | 52w low | $1.96 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$26.8M | -$26.2M | -$37.5M | -$26.0M | -$21.5M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$29.3M | -$28.3M | -$39.8M | -$27.9M | -$24.0M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $10.8M |
| Op margin | — | — | — | -68.5% |
| Net income | -$103M | -$79.3M | -$46.5M | -$7.3M |
| Gross margin | — | — | — | 42.8% |
| Gross profit | — | — | — | $4.6M |
| Operating income | -$114M | -$66.8M | -$40.9M | -$7.4M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Perspective's Cancer Therapy Candidate Receives FDA Fast Track Designation; Shares Rise Pre-Bell
2026-10-02 · Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026
2026-09-18 · William Blair Initiates Perspective Therapeutics With Outperform Rating
2026-09-14 · Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell
2026-08-19 · BMO Capital Initiates Perspective Therapeutics at Outperform
2026-08-11 · Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says
2026-08-10 · Perspective Therapeutics: Q2 Earnings Snapshot
2026-08-10 · Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results
Price (daily)
Full chart · RSI · MACD · patterns